
Hanoi (VNA) – The Philippines’ Food and Drug Administration (FDA) on December 23 approvedemergency use of a COVID-19 antiviral pill for adultpatients at risk of developing severe illness, and a COVID-19 vaccine for children aged 5-11.
According to FDA General Director Rolando Enrique Domingo, the agency grantedemergency use authorisation for Molnarz, a brand of the antiviral molnupiravir, whichis developed by the US pharmaceutical firm Merck and distributed by FabercoLife Sciences.
Domingo said the drug is indicated for adults aged 18 andabove with mild to moderate COVID-19 who have risk factors for developingsevere illness.
The FDA has also approved the emergency useauthorisation for Pfizer-BioNTech's COVID-19 vaccine for the 5 -11 agegroup with a dose lower than the standard dose for adults and adolescents.
Pfizer and BioNTech areapplying emergency use authorisation ofa two-dose regimen of their 10-microgram dose for children aged 5 -11. The two shots would be administered three weeks apart.
According to Domingo, his country planned tostart vaccinating children aged 5-11 against COVID-19 from January 2022./.